Abstracts Archive - Page 830 of 2425 - ACR Meeting Abstracts

Abstract Number: 1074 • 2019 ACR/ARP Annual Meeting
Epigenetic Regulation-Mediated Reduction in the Expression of Prostacyclin Receptor and Prostacyclin Synthase in Scleroderma Skin, Vascular Smooth Muscle Cells, and Microvascular Endothelial Cells
Yongqing Wang ¹, nezam Altorok ² and Bashar Kahaleh², ¹University of Toeldo, TOLEDO, OH, ²University of Toledo, Toledo, OH
Background/Purpose: Progressive functional and structural vascular disorder is one of the hallmark features of Systemic Sclerosis (Scleroderma, SSc). Vascular dysfunction lead to dysregulated vascular tone…
Abstract Number: 1075 • 2019 ACR/ARP Annual Meeting
The Impact of Race on Birth Outcomes Among Women with Autoimmune Rheumatic Diseases
Lena Sabih¹, Jennifer Strouse ¹, Nichole Nidey ², Gretchen Bandoli ³, Rebecca Baer ⁴, Sky Feuer ⁵, Laura Jelliffe-Pawlowski ⁵, Christina Chambers ⁶, Kelli Ryckman ² and Namrata Singh ⁷, ¹University of Iowa Hospitals and Clinics, Iowa City, ²UIOWA, Iowa City, ³University of California, San Diego, La Jolla, ⁴UCSD, La Jolla, ⁵UCSF, San Francisco, ⁶UCSD, San Diego, ⁷University of Iowa, Iowa City
Background/Purpose: Autoimmune rheumatic diseases (ARDs) are associated with adverse pregnancy outcomes (APOs). There are only a small number of studies that have looked at the…
Abstract Number: 1076 • 2019 ACR/ARP Annual Meeting
Incidence of Non-serious Infections Among Live Born Infants Born to Mothers Who Used Biologic Medications During Pregnancy for the Treatment of Autoimmune Diseases
Christina Chambers¹, Yunjun Luo ², Diana L. Johnson ², Kenneth Lyons Jones ² and Ronghui Xu ², ¹University of California San Diego, La Jolla, ²University of California, San Diego, La Jolla
Background/Purpose: In infants whose mothers were treated with biologic therapies during pregnancy, there has been a theoretical concern regarding potential risk of infections. Several recent…
Abstract Number: 1077 • 2019 ACR/ARP Annual Meeting
Mediation of Adverse Pregnancy Outcomes in Autoimmune Conditions by Pregnancy Complications
Christina Chambers¹, Gretchen Bandoli ², Namrata Singh ³, Jennifer Strouse ⁴, Rebecca Baer ⁵, Brittney Donovan ⁶, Sky Feuer ⁷, Nichole Nidey ⁶, Kelli Ryckman ⁶ and Laura Jelliffe-Pawlowski ⁷, ¹University of California San Diego, La Jolla, ²University of California, San Diego, La Jolla, ³University of Iowa, Iowa City, ⁴University of Iowa Hospitals and Clinics, Iowa City, ⁵UCSD, La Jolla, ⁶UIOWA, Iowa City, ⁷UCSF, San Francisco
Background/Purpose: Autoimmune conditions are associated with an increased risk of adverse pregnancy complications and outcomes, suggesting that pregnancy complications may mediate the excess risk. We…
Abstract Number: 1078 • 2019 ACR/ARP Annual Meeting
Cardiovascular Risk Awareness in Patients with Rheumatic Diseases: A Case-Control Study
Dionicio Angel Galarza-Delgado ¹, Iris Colunga-Pedraza ², Jose Azpiri-Lopez ², Karla Paola Cuellar-Calderon², Ileana Cecilia Reynosa-Silva ², Marielva Castro-Gonzalez ² and Carolina Marlene Martinez-Flores ², ¹Universidad Autonoma de Nuevo Leon "Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico, ²Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico
Background/Purpose: Cardiovascular diseases are among the most common comorbidities in patients with rheumatic diseases (RD) and leads them to an overall increase of mortality in…
Abstract Number: 1079 • 2019 ACR/ARP Annual Meeting
Assessing Psoriatic Arthritis Treatment Trends and Patient Journeys Between 2012 and 2018
M. Elaine Husni ¹, Brian Ung², Sven Richter ², Corey Pelletier ² and Marc Tian ², ¹Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Celgene Corporation, Summit
Background/Purpose: Many new PsA treatments have emerged without clear guidelines on which therapy to use initially. We describe PsA treatment trends and patient journeys between…
Abstract Number: 1080 • 2019 ACR/ARP Annual Meeting
Biosimilar Etanercept Use in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis: The RHUMADATA® Registry Experience
Cristiano S. Moura ¹, Denis Choquette ², Louis Coupal ³, Louis Bessette ⁴ and Sasha Bernatsky⁵, ¹McGill University Health Centre, Montreal, QC, Canada, ²Institut de Recherche en Rhumatologie de Montréal, University of Montreal, Québec, Canada., Montreal, QC, Canada, ³Institut de Recherche en Rhumatologie de Montréal, Montreal, QC, Canada, ⁴Laval University, Quebec City, QC, Canada, ⁵Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Biosimilars hold the potential to improve access to needed therapies at a reduced cost. In Canada, biosimilar etanercept (bsETA-Brenzys® and Erelzi®) were recently approved…
Abstract Number: 1081 • 2019 ACR/ARP Annual Meeting
Characteristics of Patients with Seropositive or Seronegative Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from the US-Based Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
Alexis Ogdie¹, Mei Liu ², Sabrina Rebello ², Angel Cronin ², Blessing Dube ², Robert McLean ², Esther Yi ³, Peter Hur ³ and Philip Mease ⁴, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) share many clinical features but are differentiated by key clinical and molecular characteristics. Patients…
Abstract Number: 1082 • 2019 ACR/ARP Annual Meeting
Cancer Risk in Patients with Ankylosing Spondylitis: A Nationwide Population-based Dynamic Cohort Study from Korea
Eunyoung Lee¹, Kyung-Do Han ², Yeong-Wook Song ³ and Eun Young Lee ¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Republic of Korea, ²Department of Biostatistics, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Seoul, Republic of Korea, ³Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: The aim of this study is to determine the risk of overall malignancy and site-specific cancer in ankylosing spondylitis (AS) patients compared with patients…
Abstract Number: 1083 • 2019 ACR/ARP Annual Meeting
Patient Reported Outcomes over Time in 25,988 Axial Spondyloarthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Clinical Practice – Is PRO Remission Achieved? Results from the EuroSpA Collaboration
Lykke Midtbøll Ørnbjerg¹, Johan Askling ², Anne Gitte Loft ³, Michael J. Nissen ⁴, Herman Mann ⁵, Haner Direskeneli ⁶, Florenzo Iannone ⁷, Joe Sexton ⁸, Dan Nordström ⁹, Maria José Santos ¹⁰, Catalin Codreanu ¹¹, Manuel Pombo-Suarez ¹², Ziga Rotar ¹³, Bjorn Gudbjornsson ¹⁴, Irene van der Horst-Bruinsma ¹⁵, Ulf Lindström ¹⁶, Adrian Ciurea ¹⁷, Karel Pavelka ⁵, Neslihan Yilmaz ¹⁸, Elisa Gremese ¹⁹, Eirik Kristianslund ²⁰, Anna Mari Hokkanen ²¹, Anabela Barcelos ²², Ruxandra IONESCU ²³, Carlos Sánchez-Piedra ²⁴, Matija Tomsic ²⁵, Arni Jon Geirsson ²⁶, Marleen van de Sande ¹⁵, Gary Macfarlane ²⁷, Cecilie Heegaard Brahe ²⁸, Merete Lund Hetland ¹ and Mikkel Østergaard ²⁹, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²Karolinska Institutet, Stockholm, Sweden, ³Department of Rheumatology, Aarhus University Hospital., Aarhus, Denmark, ⁴University Hospital Geneva, Geneva, Switzerland, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁶TURKBIO registry and Marmara University School of Medicin, Division of Rheumatology, Istanbul, Turkey, ⁷Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ⁸Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ⁹Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ¹⁰Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹¹Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹²Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ¹³UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹⁴Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹⁵Amsterdam University Medical Center, Amsterdam, Netherlands, ¹⁶University of Gothenburg, Gothenburg, Sweden, ¹⁷University Hospital Zürich, Zürich, Switzerland, ¹⁸TURKBIO registry and Bilim University School of Medicin, Division of Rheumatology, Istanbul, Turkey, ¹⁹Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy, ²⁰Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ²¹Helsinki University Hospital, Helsinki, Finland, ²²Centro Hospitalar Baixo Vouga | iBemed, University of Aveiro, Aveiro, Portugal, ²³SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁴Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²⁵Department of Rheumatology, University Medical Centre, Ljubjana, Slovenia, ²⁶Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, ²⁷University of Aberdeen, Aberdeen, United Kingdom, ²⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ²⁹Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Treatment effectiveness in patients with axial spondylarthritis (axSpA) is evaluated by a combination of objective markers of disease activity and patient reported outcomes (PROs),…
Abstract Number: 1084 • 2019 ACR/ARP Annual Meeting
Predicting ASDAS Inactive Disease After 6 Months of TNFi Treatment in Bio-Naive Axial Spondyloarthritis Patients Treated in Clinical Practice – Results from the EuroSpA Collaboration
Lykke Midtbøll Ørnbjerg¹, Stylianos Georgiadis ², Ulf Lindström ³, Anne Gitte Loft ⁴, Adrian Ciurea ⁵, Herman Mann ⁶, Nurullah Akkoç ⁷, Florenzo Iannone ⁸, Eirik Kristianslund ⁹, Anna Mari Hokkanen ¹⁰, Maria José Santos ¹¹, Catalin Codreanu ¹², Carlos Sánchez-Piedra ¹³, Matija Tomsic ¹⁴, Bjorn Gudbjornsson ¹⁵, Irene van der Horst-Bruinsma ¹⁶, Johan Askling ¹⁷, Michael J. Nissen ¹⁸, Karel Pavelka ⁶, Ozgül Gunduz ⁷, Fabiola Atzeni ¹⁹, Joe Sexton ²⁰, Dan Nordström ²¹, Helena Santos ²², Ruxandra IONESCU ²³, Manuel Pombo-Suarez ²⁴, Ziga Rotar ²⁵, Arni Jon Geirsson ²⁶, Marleen van de Sande ¹⁶, Gary Macfarlane ²⁷, Brigitte Michelsen ²⁸, Merete Lund Hetland ¹ and Mikkel Østergaard ²⁹, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ³University of Gothenburg, Gothenburg, Sweden, ⁴Department of Rheumatology, Aarhus University Hospital., Aarhus, Denmark, ⁵University Hospital Zürich, Zürich, Switzerland, ⁶Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁷Division of Rheumatology, Celal Bayar University School of Medicine, Manisa, Turkey, Manisa, Turkey, ⁸Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ⁹Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ¹⁰Helsinki University Hospital, Helsinki, Finland, ¹¹Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹²Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹³Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ¹⁴Department of Rheumatology, University Medical Centre, Ljubjana, Slovenia, ¹⁵Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ¹⁷Karolinska Institutet, Stockholm, Sweden, ¹⁸University Hospital Geneva, Geneva, Switzerland, ¹⁹Department of Medicine, Messina, Italy, ²⁰Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ²¹Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ²²Instituto Português de Reumatologia (IPR), Lisbon, Portugal, ²³SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁴Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ²⁵UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ²⁶Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, ²⁷University of Aberdeen, Aberdeen, United Kingdom, ²⁸EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark, ²⁹Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) have vastly improved prognosis in patients with axial spondyloarthritis (axSpA). However, many patients treated with TNFi still fail to…
Abstract Number: 1085 • 2019 ACR/ARP Annual Meeting
Probiotic Use and Psoriatic Arthritis Disease Activity
Madison Grinnell¹, Kristin Wipfler ², Alexis Ogdie ³ and Kaleb Michaud ⁴, ¹University of Nebraska College of Medicine, OMAHA, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ³Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Probiotics have been hypothesized to mediate inflammation through gut microbiome modulation, and growing evidence has suggested that our intestinal gut microbiome may play a…
Abstract Number: 1086 • 2019 ACR/ARP Annual Meeting
Psoriatic Arthritis – Epidemiology, Incidence Rate in Psoriasis Patients, Comorbidity Profiles and Risk Factor Analysis
Jürgen Rech¹, Michael Sticherling ², Mona Biermann ³, Benjamin Häberle ³ and Maximilian Reinhardt ⁴, ¹Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ²Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Bayern, Germany, ³Medical Affairs, Novartis Pharma GmbH, Nürnberg, Germany, Nürnberg, Bayern, Germany, ⁴Medical Affairs, Novartis Pharma GmbH, Nürnberg, Germany, Nürnberg, Germany
Background/Purpose: Psoriasis (PsO) is a systemic inflammatory disease accompanied by comorbidities such as depression, cardiovascular diseases or metabolic syndrome. Approximately 10 - 27% of PsO…
Abstract Number: 1087 • 2019 ACR/ARP Annual Meeting
Golimumab Improves Work Productivity and Activity and Quality of Life in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Final Results from a Non-Interventional Study in Germany (GO-ART)
Klaus Krüger¹, Sven Remstedt ², Astrid Thiele ³ and Ines Klaudius ⁴, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheuma Praxis Berlin, Berlin, Germany, ³Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, ⁴MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: Golimumab (GLM) has shown its efficacy and tolerability in various randomized clinical trials. Systemic data for GLM regarding health-economic parameters in daily clinical practice…
Abstract Number: 1088 • 2019 ACR/ARP Annual Meeting
Does Drug Effectiveness of 2nd and 3rd TNF Inhibitors in Patients with Psoriatic Arthritis Depend on the Reason for Withdrawal from the Previous Treatment? – Results from the EuroSpA Research Collaboration
Cecilie Heegaard Brahe¹, Lykke Midtbøll Ørnbjerg ¹, Lennart Jacobsson ², Michael J. Nissen ³, Eirik Kristianslund ⁴, Herman Mann ⁵, Maria José Santos ⁶, Manuel Pombo-Suarez ⁷, Dan Nordström ⁸, Ziga Rotar ⁹, Bjorn Gudbjornsson ¹⁰, Fatos Onen ¹¹, Catalin Codreanu ¹², Anne Gitte Loft ¹³, Ulf Lindström ¹⁴, Burkhard Moeller ¹⁵, Joe Sexton ¹⁶, Karel Pavelka ⁵, Anabela Barcelos ¹⁷, Carlos Sánchez-Piedra ¹⁸, Kari K. Eklund ¹⁹, Matija Tomsic ²⁰, Thorvardur J Love ²¹, Gercek Can ²², Ruxandra IONESCU ²³, Marleen van de Sande ²⁴, Irene van der Horst-Bruinsma ²⁵, Gareth Jones ²⁶, Florenzo Iannone ²⁷, Brigitte Michelsen ¹, Lise Hyldstrup ²⁸, Niels Steen Krogh ²⁹, Mikkel Østergaard ³⁰ and Merete Lund Hetland ³¹, ¹EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark, ²Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, ³University Hospital Geneva, Geneva, Switzerland, ⁴Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁶Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ⁷Rheumatology Unit, Clinical University Hospital of Santiago de Compostela,, Santiago, Spain, ⁸Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ⁹UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹⁰Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹¹Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey, ¹²Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ¹⁴University of Gothenburg, Gothenburg, Sweden, ¹⁵University Hospital Bern, Bern, Switzerland, ¹⁶Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ¹⁷Centro Hospitalar Baixo Vouga | iBemed, University of Aveiro, Aveiro, Portugal, ¹⁸Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ¹⁹ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, ²⁰Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ²¹Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ²²TURKBIO Registry and Division of Rheumatology, School of Medicine Dokuz Eylul University,, Izmir, Turkey, ²³SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁴Amsterdam UMC, Amsterdam, Netherlands, ²⁵Amsterdam University Medical Center, Amsterdam, Netherlands, ²⁶University of Aberdeen, Aberdeen, United Kingdom, ²⁷Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ²⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ²⁹Zitelab / DANBIO, Copenhagen, Denmark, ³⁰Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ³¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are efficacious in patients with psoriatic arthritis (PsA), but some patients switch to a different TNFi because of adverse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].